289 related articles for article (PubMed ID: 31519161)
41. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans.
Bond GL; Hu W; Bond EE; Robins H; Lutzker SG; Arva NC; Bargonetti J; Bartel F; Taubert H; Wuerl P; Onel K; Yip L; Hwang SJ; Strong LC; Lozano G; Levine AJ
Cell; 2004 Nov; 119(5):591-602. PubMed ID: 15550242
[TBL] [Abstract][Full Text] [Related]
42. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
43. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes.
Ard PG; Chatterjee C; Kunjibettu S; Adside LR; Gralinski LE; McMahon SB
Mol Cell Biol; 2002 Aug; 22(16):5650-61. PubMed ID: 12138177
[TBL] [Abstract][Full Text] [Related]
44. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.
Dornan D; Shimizu H; Mah A; Dudhela T; Eby M; O'rourke K; Seshagiri S; Dixit VM
Science; 2006 Aug; 313(5790):1122-6. PubMed ID: 16931761
[TBL] [Abstract][Full Text] [Related]
45. Mdm2 and MdmX RING Domains Play Distinct Roles in the Regulation of p53 Responses: A Comparative Study of Mdm2 and MdmX RING Domains in U2OS Cells.
Egorova O; Lau HH; McGraphery K; Sheng Y
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32075226
[TBL] [Abstract][Full Text] [Related]
46. UNC119 is a binding partner of tumor suppressor Ras-association domain family 6 and induces apoptosis and cell cycle arrest by MDM2 and p53.
Iwasa H; Sarkar A; Shimizu T; Sawada T; Hossain S; Xu X; Maruyama J; Arimoto-Matsuzaki K; Withanage K; Nakagawa K; Kurihara H; Kuroyanagi H; Hata Y
Cancer Sci; 2018 Sep; 109(9):2767-2780. PubMed ID: 29931788
[TBL] [Abstract][Full Text] [Related]
47. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation.
Stommel JM; Wahl GM
Cell Cycle; 2005 Mar; 4(3):411-7. PubMed ID: 15684615
[TBL] [Abstract][Full Text] [Related]
48. Circular RNA CDR1as disrupts the p53/MDM2 complex to inhibit Gliomagenesis.
Lou J; Hao Y; Lin K; Lyu Y; Chen M; Wang H; Zou D; Jiang X; Wang R; Jin D; Lam EW; Shao S; Liu Q; Yan J; Wang X; Chen P; Zhang B; Jin B
Mol Cancer; 2020 Sep; 19(1):138. PubMed ID: 32894144
[TBL] [Abstract][Full Text] [Related]
49. ATM and Chk2-dependent phosphorylation of MDMX contribute to p53 activation after DNA damage.
Chen L; Gilkes DM; Pan Y; Lane WS; Chen J
EMBO J; 2005 Oct; 24(19):3411-22. PubMed ID: 16163388
[TBL] [Abstract][Full Text] [Related]
50. Acetylation-dependent regulation of MDM2 E3 ligase activity dictates its oncogenic function.
Nihira NT; Ogura K; Shimizu K; North BJ; Zhang J; Gao D; Inuzuka H; Wei W
Sci Signal; 2017 Feb; 10(466):. PubMed ID: 28196907
[TBL] [Abstract][Full Text] [Related]
51. Cancer-associated mutations in the MDM2 zinc finger domain disrupt ribosomal protein interaction and attenuate MDM2-induced p53 degradation.
Lindström MS; Jin A; Deisenroth C; White Wolf G; Zhang Y
Mol Cell Biol; 2007 Feb; 27(3):1056-68. PubMed ID: 17116689
[TBL] [Abstract][Full Text] [Related]
52. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
53. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
54. The RNF20/40 complex regulates p53-dependent gene transcription and mRNA splicing.
Wu C; Cui Y; Liu X; Zhang F; Lu LY; Yu X
J Mol Cell Biol; 2020 Feb; 12(2):113-124. PubMed ID: 31152661
[TBL] [Abstract][Full Text] [Related]
55. A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.
Post SM; Quintás-Cardama A; Pant V; Iwakuma T; Hamir A; Jackson JG; Maccio DR; Bond GL; Johnson DG; Levine AJ; Lozano G
Cancer Cell; 2010 Sep; 18(3):220-30. PubMed ID: 20832750
[TBL] [Abstract][Full Text] [Related]
56. FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53.
Ochocka AM; Kampanis P; Nicol S; Allende-Vega N; Cox M; Marcar L; Milne D; Fuller-Pace F; Meek D
FEBS Lett; 2009 Feb; 583(4):621-6. PubMed ID: 19166840
[TBL] [Abstract][Full Text] [Related]
57. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
Gupta A; Shah K; Oza MJ; Behl T
Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
[TBL] [Abstract][Full Text] [Related]
58. MYBBP1A suppresses breast cancer tumorigenesis by enhancing the p53 dependent anoikis.
Akaogi K; Ono W; Hayashi Y; Kishimoto H; Yanagisawa J
BMC Cancer; 2013 Feb; 13():65. PubMed ID: 23388179
[TBL] [Abstract][Full Text] [Related]
59. The RNA binding protein RALY suppresses p53 activity and promotes lung tumorigenesis.
Hu H; Zhao K; Fang D; Wang Z; Yu N; Yao B; Liu K; Wang F; Mei Y
Cell Rep; 2023 Apr; 42(4):112288. PubMed ID: 36952348
[TBL] [Abstract][Full Text] [Related]
60. The p53 protein induces stable miRNAs that have the potential to modify subsequent p53 responses.
Cabrita MA; Bose R; Vanzyl EJ; Pastic A; Marcellus KA; Pan E; Hamill JD; McKay BC
Gene; 2017 Apr; 608():86-94. PubMed ID: 28119089
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
